Avascular necrosis is strongly associated with prior chemotherapy treatment. Although initial x-rays may appear normal in patients with this condition, it is unlikely that they would not reveal any metastatic deposits that could cause pain.

Understanding Avascular Necrosis of the Hip

Avascular necrosis of the hip is a condition where bone tissue dies due to a loss of blood supply, leading to bone destruction and loss of joint function. This condition typically affects the epiphysis of long bones, such as the femur. There are several causes of avascular necrosis, including long-term steroid use, chemotherapy, alcohol excess, and trauma.

Initially, avascular necrosis may not present with any symptoms, but as the condition progresses, pain in the affected joint may occur. Plain x-ray findings may be normal in the early stages, but osteopenia and microfractures may be seen. As the condition worsens, collapse of the articular surface may result in the crescent sign.

MRI is the preferred investigation for avascular necrosis as it is more sensitive than radionuclide bone scanning. In severe cases, joint replacement may be necessary to manage the condition. Understanding the causes, features, and management of avascular necrosis of the hip is crucial for early detection and effective treatment.

The combination of azathioprine and allopurinol can lead to a serious interaction that results in bone marrow suppression. This is particularly concerning for patients with Crohn’s disease who are already taking azathioprine, as both medications inhibit xanthine oxidase.

Azathioprine is a medication that is broken down into mercaptopurine, which is an active compound that inhibits the production of purine. To determine if someone is at risk for azathioprine toxicity, a test for thiopurine methyltransferase (TPMT) may be necessary. Adverse effects of this medication include bone marrow depression, which can be detected through a full blood count if there are signs of infection or bleeding, as well as nausea, vomiting, pancreatitis, and an increased risk of non-melanoma skin cancer. It is important to note that there is a significant interaction between azathioprine and allopurinol, so lower doses of azathioprine should be used in conjunction with allopurinol. Despite these potential side effects, azathioprine is generally considered safe to use during pregnancy.

To manage plantar fasciitis, it is recommended to start with rest, stretching, and weight loss if the patient is overweight. Stretching exercises targeting the plantar fascia and Achilles tendon should be done three times a day. Orthotics and NSAIDs can be used, but only after trying the initial measures. It is important to note that the patient has asthma, so prescribing ibuprofen would not be appropriate. While a 6 week review is appropriate, it should also include monitoring weight loss as a key factor in managing the condition. Therefore, weight loss should be considered as the best initial step, given the patient’s BMI of 29.

Understanding Plantar Fasciitis

Plantar fasciitis is a prevalent condition that causes heel pain in adults. The pain is typically concentrated around the medial calcaneal tuberosity, which is the bony bump on the inside of the heel. This condition occurs when the plantar fascia, a thick band of tissue that runs along the bottom of the foot, becomes inflamed or irritated.

To manage plantar fasciitis, it is essential to rest the feet as much as possible. Wearing shoes with good arch support and cushioned heels can also help alleviate the pain. Insoles and heel pads may also be beneficial in providing additional support and cushioning. It is important to note that plantar fasciitis can take time to heal, and it is crucial to be patient and consistent with treatment. By taking these steps, individuals can effectively manage their plantar fasciitis and reduce their discomfort.

The measurement of disease activity in rheumatoid arthritis is done using the DAS28 score. This score evaluates the level of disease activity by assessing 28 joints, hence the name DAS28, where DAS stands for disease activity score.

Managing Rheumatoid Arthritis with Disease-Modifying Therapies

The management of rheumatoid arthritis (RA) has significantly improved with the introduction of disease-modifying therapies (DMARDs) in the past decade. Patients with joint inflammation should start a combination of DMARDs as soon as possible, along with analgesia, physiotherapy, and surgery. In 2018, NICE updated their guidelines for RA management, recommending DMARD monotherapy with a short course of bridging prednisolone as the initial step. Monitoring response to treatment is crucial, and NICE suggests using a combination of CRP and disease activity to assess it. Flares of RA are often managed with corticosteroids, while methotrexate is the most widely used DMARD. Other DMARDs include sulfasalazine, leflunomide, and hydroxychloroquine. TNF-inhibitors are indicated for patients with an inadequate response to at least two DMARDs, including methotrexate. Etanercept, infliximab, and adalimumab are some of the TNF-inhibitors available, each with their own risks and administration methods. Rituximab and Abatacept are other DMARDs that can be used, but the latter is not currently recommended by NICE.

Patients who are on steroids or are going to be on steroids for 3 or more months and have a T-score < -1.5 should be offered prophylactic bisphosphonates, regardless of their age. However, patients over the age of 65 years or those who have previously experienced a fragility fracture should be offered bone protection if they are on steroids. For patients under the age of 65, a T-score measurement should be taken to screen for low bone density. If the T-score is <-1.5, bone protection should be offered. Other factors such as smoking, high alcohol intake, low BMI, and family history should be considered as indicators to screen for osteoporosis, but not necessarily to offer bone protection. Managing the Risk of Osteoporosis in Patients Taking Corticosteroids Osteoporosis is a significant risk for patients taking corticosteroids, which are commonly used in clinical practice. To manage this risk appropriately, the 2002 Royal College of Physicians (RCP) guidelines provide a concise guide to prevention and treatment. According to these guidelines, the risk of osteoporosis increases significantly when a patient takes the equivalent of prednisolone 7.5mg a day for three or more months. Therefore, it is important to manage patients in an anticipatory manner, starting bone protection immediately if it is likely that the patient will need to take steroids for at least three months. The RCP guidelines divide patients into two groups based on age and fragility fracture history. Patients over the age of 65 years or those who have previously had a fragility fracture should be offered bone protection. For patients under the age of 65 years, a bone density scan should be offered, with further management dependent on the T score. If the T score is greater than 0, patients can be reassured. If the T score is between 0 and -1.5, a repeat bone density scan should be done in 1-3 years. If the T score is less than -1.5, bone protection should be offered. The first-line treatment for corticosteroid-induced osteoporosis is alendronate. Patients should also be replete in calcium and vitamin D. By following these guidelines, healthcare professionals can effectively manage the risk of osteoporosis in patients taking corticosteroids.

The symptoms observed in the clinic and the findings from laboratory tests indicate the possibility of systemic lupus erythematosus (SLE). A confirmation of the diagnosis can be obtained through the detection of anti-dsDNA antibodies.

Systemic lupus erythematosus (SLE) can be investigated through various tests, including antibody tests. ANA testing is highly sensitive, making it useful for ruling out SLE, but it has low specificity. About 99% of SLE patients are ANA positive. Rheumatoid factor testing is positive in 20% of SLE patients. Anti-dsDNA testing is highly specific (>99%), but less sensitive (70%). Anti-Smith testing is also highly specific (>99%), but only 30% of SLE patients test positive. Other antibody tests include anti-U1 RNP, SS-A (anti-Ro), and SS-B (anti-La).

Monitoring of SLE can be done through various markers, including inflammatory markers such as ESR. During active disease, CRP levels may be normal, but a raised CRP may indicate an underlying infection. Complement levels (C3, C4) are low during active disease due to the formation of complexes that lead to the consumption of complement. Anti-dsDNA titres can also be used for disease monitoring, but it is important to note that they are not present in all SLE patients. Proper monitoring of SLE is crucial for effective management of the disease.

Cubital tunnel syndrome is the correct answer as it is caused by the compression of the ulnar nerve and can result in tingling or numbness in the 4th and 5th fingers. Tinel’s sign, which involves tapping on the affected nerve to reproduce symptoms, is positive in this condition. Brachial plexus injury is not the correct answer as the question specifies that the issue is atraumatic and the neurological examination is normal. Carpal tunnel syndrome affects the median nerve, which provides sensation to the first, second, and part of the third digit, but Tinel’s sign can also be used to check the ulnar nerve. While a medial epicondyle fracture may cause similar symptoms due to the path of the ulnar nerve, the absence of trauma makes this answer unlikely.

Understanding Cubital Tunnel Syndrome

Cubital tunnel syndrome is a condition that occurs when the ulnar nerve is compressed as it passes through the cubital tunnel. This can cause a range of symptoms, including tingling and numbness in the fourth and fifth fingers, which may start off intermittent but eventually become constant. Over time, patients may also experience weakness and muscle wasting. Pain is often worse when leaning on the affected elbow, and there may be a history of osteoarthritis or prior trauma to the area.

Diagnosis of cubital tunnel syndrome is usually made based on clinical features, although nerve conduction studies may be used in selected cases. Management of the condition typically involves avoiding aggravating activities, undergoing physiotherapy, and receiving steroid injections. In cases where these measures are not effective, surgery may be necessary. By understanding the symptoms and treatment options for cubital tunnel syndrome, patients can take steps to manage their condition and improve their quality of life.

Enteropathic arthritis is a type of spondyloarthropathy that is seronegative and linked to gastrointestinal disorders.

Seronegative Spondyloarthropathies

Seronegative spondyloarthropathies are a group of inflammatory joint diseases that are characterized by the absence of rheumatoid factor and the presence of HLA-B27. These conditions commonly affect the spine and sacroiliac joints, causing pain and stiffness. Other common features include peripheral arthritis, which is usually asymmetrical, and enthesopathy, which can cause conditions such as Achilles tendonitis and plantar fasciitis.

In addition to joint symptoms, seronegative spondyloarthropathies can also cause extra-articular manifestations such as uveitis, pulmonary fibrosis (upper zone), amyloidosis, and aortic regurgitation. These conditions can be associated with other underlying diseases such as inflammatory bowel disease (IBD).

The most common types of seronegative spondyloarthropathies include ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and enteropathic arthritis (associated with IBD). Early diagnosis and treatment are important in managing these conditions and preventing long-term complications.

The recommended treatment for systemic lupus erythematosus (SLE) is hydroxychloroquine, which is a disease-modifying anti-rheumatic drug (DMARD). A patient presenting with symptoms such as fatigue, musculoskeletal pain, low mood, and lymphadenopathy, along with positive results for antinuclear antibodies and double-stranded DNA antibodies, may be diagnosed with SLE. Hydroxychloroquine works by increasing lysosomal pH in antigen-presenting cells, which interferes with activity and downregulates the inappropriate autoimmune response. Cyclophosphamide, an alkylating agent used in cancer treatment, is not appropriate for SLE management unless there is renal involvement. Methotrexate, another DMARD, can be used as a steroid-sparing agent in conjunction with prednisolone if the patient’s symptoms are not controlled by NSAIDs and hydroxychloroquine. Prednisolone, a corticosteroid, is typically reserved for patients with internal organ involvement or if their symptoms are not controlled by other medications due to the long-term risks associated with steroid use.

Managing Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects various organs and tissues in the body. To manage SLE, several treatment options are available. Nonsteroidal anti-inflammatory drugs (NSAIDs) can help relieve joint pain and inflammation. It is also important to use sunblock to prevent skin damage and flare-ups triggered by sun exposure.

Hydroxychloroquine is considered the treatment of choice for SLE. It can help reduce disease activity and prevent flares. However, if SLE affects internal organs such as the kidneys, nervous system, or eyes, additional treatment may be necessary. In such cases, prednisolone and cyclophosphamide may be prescribed to manage inflammation and prevent organ damage.

To summarize, managing SLE involves a combination of medication and lifestyle changes. NSAIDs and sunblock can help manage symptoms, while hydroxychloroquine is the preferred treatment for reducing disease activity. If SLE affects internal organs, additional medication may be necessary to prevent organ damage.

Pain in the distribution of the lateral cutaneous nerve of the thigh is a common symptom of Meralgia parasthetica. This pain is often worsened by standing and relieved by sitting, and is accompanied by altered sensation in the anterolateral aspect of the thigh. Meralgia parasthetica can be caused by pregnancy, obesity, tense ascites, trauma, or surgery, and is more prevalent in individuals with diabetes.

In contrast, fibromyalgia typically presents with pain in the neck and shoulders, along with other symptoms such as fatigue, muscle stiffness, difficulty sleeping, and cognitive impairment. Fibromyalgia pain does not typically affect the lateral thigh.

L3 lumbar radiculopathy, on the other hand, causes pain in the lower back and hip that radiates down into the leg, often accompanied by muscle weakness.

Osteoarthritis is characterized by joint pain and stiffness in the hips or knees, and is more common in older individuals, females, and those who are overweight. It does not typically cause changes in sensation in the thigh.

Understanding Meralgia Paraesthetica

Meralgia paraesthetica is a condition characterized by paraesthesia or anaesthesia in the distribution of the lateral femoral cutaneous nerve (LFCN). It is caused by entrapment of the LFCN, which can be due to various factors such as trauma, iatrogenic causes, or neuroma. Although not rare, it is often underdiagnosed.

The LFCN is a sensory nerve that originates from the L2/3 segments and runs beneath the iliac fascia before exiting through the lateral aspect of the inguinal ligament. Compression of the nerve can occur anywhere along its course, but it is most commonly affected as it curves around the anterior superior iliac spine. Meralgia paraesthetica is more common in men than women and is often seen in those aged between 30 and 40.

Patients with meralgia paraesthetica typically experience burning, tingling, coldness, or shooting pain, as well as numbness and deep muscle ache in the upper lateral aspect of the thigh. Symptoms are usually aggravated by standing and relieved by sitting. The condition can be mild and resolve spontaneously or severely restrict the patient for many years.

Diagnosis of meralgia paraesthetica can be made based on the pelvic compression test, which is highly sensitive. Injection of the nerve with local anaesthetic can also confirm the diagnosis and provide relief. Ultrasound is effective both for diagnosis and guiding injection therapy. Nerve conduction studies may also be useful. Overall, understanding meralgia paraesthetica is important for prompt diagnosis and management of this condition.

The patient exhibits all the symptoms of CREST syndrome except for dysphagia caused by oesophageal dysmotility. These symptoms include calcinosis (white deposits), Raynaud’s phenomenon (cold, white fingertips triggered by cold weather), sclerodactyly (thickened skin on top of hands and inability to straighten fingers), and telangiectasia (excessive number of spider naevi). Gottron’s papules and dilated capillary loops are characteristic of dermatomyositis, while limited scleroderma does not typically involve internal organs, making glomerulonephritis unlikely. Although Sjogren’s syndrome can overlap with other connective tissue diseases, the patient’s lack of dysphagia makes this diagnosis less likely than CREST syndrome.

Understanding Systemic Sclerosis

Systemic sclerosis is a condition that affects the skin and other connective tissues, but its cause is unknown. It is more common in females, with three patterns of the disease. Limited cutaneous systemic sclerosis is characterised by Raynaud’s as the first sign, affecting the face and distal limbs, and associated with anti-centromere antibodies. CREST syndrome is a subtype of limited systemic sclerosis that includes Calcinosis, Raynaud’s phenomenon, oEsophageal dysmotility, Sclerodactyly, and Telangiectasia. Diffuse cutaneous systemic sclerosis affects the trunk and proximal limbs, associated with scl-70 antibodies, and has a poor prognosis. Respiratory involvement is the most common cause of death, with interstitial lung disease and pulmonary arterial hypertension being the primary complications. Renal disease and hypertension are also possible complications, and patients with renal disease should be started on an ACE inhibitor. Scleroderma without internal organ involvement is characterised by tightening and fibrosis of the skin, manifesting as plaques or linear. Antibodies such as ANA, RF, anti-scl-70, and anti-centromere are associated with different types of systemic sclerosis.

Psoas abscess is commonly caused by Staphylococcus, which is the likely culprit in this case. The patient’s lumbar tenderness and preference for a slightly flexed knee position are indicative of this condition, which is particularly risky for individuals with immunosuppression due to factors such as intravenous drug use, diabetes, or HIV. Given the patient’s recent groin abscess, it is possible that the organism responsible for that infection seeded the psoas muscle. It is important to be aware of potential complications of Staphylococcus aureus infection, such as infective endocarditis and psoas abscess, and to investigate these conditions in patients with positive blood cultures for this organism.

An iliopsoas abscess is a condition where pus accumulates in the iliopsoas compartment, which includes the iliacus and psoas muscles. There are two types of iliopsoas abscesses: primary and secondary. Primary abscesses occur due to the spread of bacteria through the bloodstream, with Staphylococcus aureus being the most common cause. Secondary abscesses are caused by underlying conditions such as Crohn’s disease, diverticulitis, colorectal cancer, UTIs, GU cancers, vertebral osteomyelitis, femoral catheterization, lithotripsy, endocarditis, and intravenous drug use. Secondary abscesses have a higher mortality rate compared to primary abscesses.

The clinical features of an iliopsoas abscess include fever, back/flank pain, limp, and weight loss. During a clinical examination, the patient is positioned supine with the knee flexed and the hip mildly externally rotated. Specific tests are performed to diagnose iliopsoas inflammation, such as placing a hand proximal to the patient’s ipsilateral knee and asking the patient to lift their thigh against the hand, which causes pain due to contraction of the psoas muscle. Another test involves lying the patient on the normal side and hyperextending the affected hip, which should elicit pain as the psoas muscle is stretched.

The investigation of choice for an iliopsoas abscess is a CT scan of the abdomen. Management involves antibiotics and percutaneous drainage, which is successful in around 90% of cases. Surgery is only indicated if percutaneous drainage fails or if there is another intra-abdominal pathology that requires surgery.

The primary investigation for patients suspected of having septic arthritis is the sampling of synovial fluid.

Septic arthritis is a joint inflammation caused by the introduction of infectious microorganisms into the joint.

Septic Arthritis in Adults: Causes, Symptoms, and Treatment

Septic arthritis is a condition that occurs when bacteria infect a joint, leading to inflammation and pain. The most common organism that causes septic arthritis in adults is Staphylococcus aureus, but in young adults who are sexually active, Neisseria gonorrhoeae is the most common organism. The infection usually spreads through the bloodstream from a distant bacterial infection, such as an abscess. The knee is the most common location for septic arthritis in adults. Symptoms include an acute, swollen joint, restricted movement, warmth to the touch, and fever.

To diagnose septic arthritis, synovial fluid sampling is necessary and should be done before administering antibiotics if necessary. Blood cultures may also be taken to identify the cause of the infection. Joint imaging may also be used to confirm the diagnosis.

Treatment for septic arthritis involves intravenous antibiotics that cover Gram-positive cocci. Flucloxacillin or clindamycin is recommended if the patient is allergic to penicillin. Antibiotic treatment is typically given for several weeks, and patients are usually switched to oral antibiotics after two weeks. Needle aspiration may be used to decompress the joint, and arthroscopic lavage may be required in some cases.

Normal blood test values, including ALP, calcium, phosphate, and PTH, are commonly observed in patients with osteoporosis. However, in cases where osteoporosis is caused by chronic use of systemic steroids, the bone profile results may still appear normal. Other conditions, such as primary hyperparathyroidism, osteomalacia, CKD, and tertiary hyperparathyroidism, may present with abnormal blood test values, including high PTH, low calcium, and/or low phosphate.

Understanding Osteoporosis

Osteoporosis is a condition that affects the skeletal system, causing a loss of bone mass. As people age, their bone mineral density decreases, but osteoporosis is defined by the World Health Organisation as having a bone mineral density of less than 2.5 standard deviations below the young adult mean density. This condition is significant because it increases the risk of fragility fractures, which can lead to significant morbidity and mortality. In fact, around 50% of postmenopausal women will experience an osteoporotic fracture at some point.

The primary risk factors for osteoporosis are age and female gender, but other factors include corticosteroid use, smoking, alcohol consumption, low body mass index, and family history. To assess a patient’s risk of developing a fragility fracture, healthcare providers may use screening tools such as FRAX or QFracture. Additionally, patients who have sustained a fragility fracture should be evaluated for osteoporosis.

To determine a patient’s bone mineral density, a dual-energy X-ray absorptiometry (DEXA) scan is used to examine the hip and lumbar spine. If either of these areas has a T score of less than -2.5, treatment is recommended. The first-line treatment for osteoporosis is typically an oral bisphosphonate such as alendronate, although other treatments are available. Overall, osteoporosis is a significant condition that requires careful evaluation and management to prevent fragility fractures and their associated complications.

It is important to note that a negative HLA-B27 result should not be used to completely rule out a diagnosis of spondyloarthritis, as there are still cases of ankylosing spondylitis that do not show this genetic marker.

Investigating and Managing Ankylosing Spondylitis

Ankylosing spondylitis is a type of spondyloarthropathy that is associated with HLA-B27. It is more commonly seen in males aged 20-30 years old. Inflammatory markers such as ESR and CRP are usually elevated, but normal levels do not necessarily rule out ankylosing spondylitis. HLA-B27 is not a reliable diagnostic tool as it can also be positive in normal individuals. The most effective way to diagnose ankylosing spondylitis is through a plain x-ray of the sacroiliac joints. However, if the x-ray is negative but suspicion for AS remains high, an MRI can be obtained to confirm the diagnosis.

Management of ankylosing spondylitis involves regular exercise, such as swimming, and the use of NSAIDs as the first-line treatment. Physiotherapy can also be helpful. Disease-modifying drugs used for rheumatoid arthritis, such as sulphasalazine, are only useful if there is peripheral joint involvement. Anti-TNF therapy, such as etanercept and adalimumab, should be given to patients with persistently high disease activity despite conventional treatments, according to the 2010 EULAR guidelines. Ongoing research is being conducted to determine whether anti-TNF therapies should be used earlier in the course of the disease. Spirometry may show a restrictive defect due to a combination of pulmonary fibrosis, kyphosis, and ankylosis of the costovertebral joints.

Temporal arthritis, also known as giant cell arthritis, is a condition that affects medium and large-sized arteries and is of unknown cause. It typically occurs in individuals over the age of 50, with the highest incidence in those in their 70s. Early recognition and treatment are crucial to minimize the risk of complications, such as permanent loss of vision. Therefore, when temporal arthritis is suspected, urgent referral for assessment by a specialist and prompt treatment with high-dose prednisolone is necessary.

Temporal arthritis often overlaps with polymyalgia rheumatica, with around 50% of patients exhibiting features of both conditions. Symptoms of temporal arthritis include headache, jaw claudication, and tender, palpable temporal artery. Vision testing is a key investigation in all patients, as anterior ischemic optic neuropathy is the most common ocular complication. This results from occlusion of the posterior ciliary artery, leading to ischemia of the optic nerve head. Fundoscopy typically shows a swollen pale disc and blurred margins. Other symptoms may include aching, morning stiffness in proximal limb muscles, lethargy, depression, low-grade fever, anorexia, and night sweats.

Investigations for temporal arthritis include raised inflammatory markers, such as an ESR greater than 50 mm/hr and elevated CRP. A temporal artery biopsy may also be performed, and skip lesions may be present. Treatment for temporal arthritis involves urgent high-dose glucocorticoids, which should be given as soon as the diagnosis is suspected and before the temporal artery biopsy. If there is no visual loss, high-dose prednisolone is used. If there is evolving visual loss, IV methylprednisolone is usually given prior to starting high-dose prednisolone. Urgent ophthalmology review is necessary, as visual damage is often irreversible. Other treatments may include bone protection with bisphosphonates and low-dose aspirin.

The anti-dsDNA test is highly specific for detecting lupus, making it useful in ruling out systemic lupus erythematosus if the results are negative. On the other hand, anti-CCP is utilized in diagnosing rheumatoid arthritis, while anti-La is primarily present in individuals with Sjogren’s syndrome. Although anti-La can also be found in those with lupus, it lacks specificity. Interestingly, infants born to mothers with anti-La and anti-Ro antibodies have an increased risk of developing neonatal lupus. ANCA is an antibody that targets neutrophils and is observed in patients with autoimmune vasculitis.

Systemic lupus erythematosus (SLE) can be investigated through various tests, including antibody tests. ANA testing is highly sensitive, making it useful for ruling out SLE, but it has low specificity. About 99% of SLE patients are ANA positive. Rheumatoid factor testing is positive in 20% of SLE patients. Anti-dsDNA testing is highly specific (>99%), but less sensitive (70%). Anti-Smith testing is also highly specific (>99%), but only 30% of SLE patients test positive. Other antibody tests include anti-U1 RNP, SS-A (anti-Ro), and SS-B (anti-La).

Monitoring of SLE can be done through various markers, including inflammatory markers such as ESR. During active disease, CRP levels may be normal, but a raised CRP may indicate an underlying infection. Complement levels (C3, C4) are low during active disease due to the formation of complexes that lead to the consumption of complement. Anti-dsDNA titres can also be used for disease monitoring, but it is important to note that they are not present in all SLE patients. Proper monitoring of SLE is crucial for effective management of the disease.

When starting allopurinol for prophylactic treatment of gout, it is important to use NSAID or colchicine ‘cover’ to prevent an acute flare up of gout. This is because starting allopurinol can trigger an acute flare up of gout. In this case, diclofenac, an NSAID, should be given alongside allopurinol initially. Azathioprine use is contraindicated alongside allopurinol due to the risk of toxicity. Febuxostat is an alternative to allopurinol but should not be used alongside it. Hydroxychloroquine and methotrexate are not used in the treatment of gout but have a role in maintenance treatment for other rheumatological diseases.

Gout is caused by chronic hyperuricaemia and is managed acutely with NSAIDs or colchicine. Urate-lowering therapy (ULT) is recommended for patients with >= 2 attacks in 12 months, tophi, renal disease, uric acid renal stones, or prophylaxis if on cytotoxics or diuretics. Allopurinol is first-line ULT, with an initial dose of 100 mg od and titrated to aim for a serum uric acid of < 300 µmol/l. Lifestyle modifications include reducing alcohol intake, losing weight if obese, and avoiding high-purine foods. Consideration should be given to stopping precipitating drugs and losartan may be suitable for patients with coexistent hypertension.

The development of avascular necrosis of the femoral head is strongly associated with long-term steroid use, as seen in this patient who is taking prednisolone for polymyalgia rheumatica.

Understanding Avascular Necrosis of the Hip

Avascular necrosis of the hip is a condition where bone tissue dies due to a loss of blood supply, leading to bone destruction and loss of joint function. This condition typically affects the epiphysis of long bones, such as the femur. There are several causes of avascular necrosis, including long-term steroid use, chemotherapy, alcohol excess, and trauma.

Initially, avascular necrosis may not present with any symptoms, but as the condition progresses, pain in the affected joint may occur. Plain x-ray findings may be normal in the early stages, but osteopenia and microfractures may be seen. As the condition worsens, collapse of the articular surface may result in the crescent sign.

MRI is the preferred investigation for avascular necrosis as it is more sensitive than radionuclide bone scanning. In severe cases, joint replacement may be necessary to manage the condition. Understanding the causes, features, and management of avascular necrosis of the hip is crucial for early detection and effective treatment.

The x-ray findings that are commonly seen in ankylosing spondylitis include subchondral erosions, sclerosis, and squaring of lumbar vertebrae. These findings are indicative of the patient’s symptoms of inflammatory joint pain, which is most likely caused by ankylosing spondylitis given their age, gender, and nature of pain. Sacroiliitis on x-ray can confirm the diagnosis of ankylosing spondylitis.

Juxta-articular osteopenia, subchondral cysts, and squaring of lumbar vertebrae are incorrect as they are not commonly seen in ankylosing spondylitis. Juxta-articular osteopenia is more commonly associated with rheumatoid arthritis, while subchondral cysts and osteophyte formation at joint margins are more common in osteoarthritis.

Subchondral sclerosis and osteophyte formation at joint margins are also incorrect as they are more commonly seen in osteoarthritis. Periarticular erosions are more commonly associated with rheumatoid arthritis and are therefore unlikely to be seen on this patient’s x-ray.

Investigating and Managing Ankylosing Spondylitis

Ankylosing spondylitis is a type of spondyloarthropathy that is associated with HLA-B27. It is more commonly seen in males aged 20-30 years old. Inflammatory markers such as ESR and CRP are usually elevated, but normal levels do not necessarily rule out ankylosing spondylitis. HLA-B27 is not a reliable diagnostic tool as it can also be positive in normal individuals. The most effective way to diagnose ankylosing spondylitis is through a plain x-ray of the sacroiliac joints. However, if the x-ray is negative but suspicion for AS remains high, an MRI can be obtained to confirm the diagnosis.

Management of ankylosing spondylitis involves regular exercise, such as swimming, and the use of NSAIDs as the first-line treatment. Physiotherapy can also be helpful. Disease-modifying drugs used for rheumatoid arthritis, such as sulphasalazine, are only useful if there is peripheral joint involvement. Anti-TNF therapy, such as etanercept and adalimumab, should be given to patients with persistently high disease activity despite conventional treatments, according to the 2010 EULAR guidelines. Ongoing research is being conducted to determine whether anti-TNF therapies should be used earlier in the course of the disease. Spirometry may show a restrictive defect due to a combination of pulmonary fibrosis, kyphosis, and ankylosis of the costovertebral joints.

Immediate bone protection should be provided to patients who are going to undergo long-term steroid treatment, especially if they are over 65 years old. In the case of this patient with giant cell arthritis, high dose prednisolone is required and therefore, immediate bone protection with alendronic acid is necessary. However, if the patient was under 65 years old, a bone density scan would be required to determine the need for bone protection medication. Merely reassuring the patient would not suffice as long-term steroid use can lead to osteoporosis, which is a significant concern for patients over 65 years old. Additionally, vitamin D and calcium supplements should be started along with bone protection medication. It is important to note that NSAIDs are not a suitable alternative to steroids for treating giant cell arthritis.

Managing the Risk of Osteoporosis in Patients Taking Corticosteroids

Osteoporosis is a significant risk for patients taking corticosteroids, which are commonly used in clinical practice. To manage this risk appropriately, the 2002 Royal College of Physicians (RCP) guidelines provide a concise guide to prevention and treatment. According to these guidelines, the risk of osteoporosis increases significantly when a patient takes the equivalent of prednisolone 7.5mg a day for three or more months. Therefore, it is important to manage patients in an anticipatory manner, starting bone protection immediately if it is likely that the patient will need to take steroids for at least three months.

The RCP guidelines divide patients into two groups based on age and fragility fracture history. Patients over the age of 65 years or those who have previously had a fragility fracture should be offered bone protection. For patients under the age of 65 years, a bone density scan should be offered, with further management dependent on the T score. If the T score is greater than 0, patients can be reassured. If the T score is between 0 and -1.5, a repeat bone density scan should be done in 1-3 years. If the T score is less than -1.5, bone protection should be offered.

The first-line treatment for corticosteroid-induced osteoporosis is alendronate. Patients should also be replete in calcium and vitamin D. By following these guidelines, healthcare professionals can effectively manage the risk of osteoporosis in patients taking corticosteroids.

The revised ARA criteria for the classification of lupus includes serositis (pleuritis or pericarditis) as a defining feature. Pericarditis is the most prevalent cardiac manifestation of SLE and is also included in the classification criteria of the British Society for Rheumatology 2018 guidelines for SLE. It is important to note that the other options are not part of these criteria, which are not comprehensive but are still considered a valuable diagnostic aid.

Understanding Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is an autoimmune disorder that affects multiple systems in the body. It is more common in women and people of Afro-Caribbean origin, and typically presents in early adulthood. The general features of SLE include fatigue, fever, mouth ulcers, and lymphadenopathy.

SLE can also affect the skin, causing a malar (butterfly) rash that spares the nasolabial folds, discoid rash in sun-exposed areas, photosensitivity, Raynaud’s phenomenon, livedo reticularis, and non-scarring alopecia. Musculoskeletal symptoms include arthralgia and non-erosive arthritis.

Cardiovascular manifestations of SLE include pericarditis and myocarditis, while respiratory symptoms may include pleurisy and fibrosing alveolitis. Renal involvement can lead to proteinuria and glomerulonephritis, with diffuse proliferative glomerulonephritis being the most common type.

Finally, neuropsychiatric symptoms of SLE may include anxiety and depression, as well as more severe manifestations such as psychosis and seizures. Understanding the various features of SLE is important for early diagnosis and management of this complex autoimmune disorder.

Nifedipine is a recommended medication for treating Raynaud’s phenomenon. Patients with this condition should be advised to keep their hands warm and quit smoking. NICE suggests other treatments such as evening primrose oil, sildenafil, and prostacyclin for severe attacks or digital gangrene. Chemical or surgical sympathectomy may be helpful for those with severe disease. Propranolol, a beta-blocker, may worsen the condition as it commonly causes cold peripheries. Ibuprofen, an analgesic, may alleviate pain but not other symptoms. Amitriptyline, a tricyclic antidepressant, is also used for neuropathic pain but not specifically for Raynaud’s.

Understanding Raynaud’s Phenomenon

Raynaud’s phenomenon is a condition where the digital arteries and cutaneous arteriole overreact to cold or emotional stress, causing an exaggerated vasoconstrictive response. It can be classified as primary or secondary. Primary Raynaud’s disease is more common in young women and presents with bilateral symptoms. On the other hand, secondary Raynaud’s phenomenon is associated with underlying connective tissue disorders such as scleroderma, rheumatoid arthritis, and systemic lupus erythematosus, among others.

Factors that suggest an underlying connective tissue disease include onset after 40 years, unilateral symptoms, rashes, presence of autoantibodies, and digital ulcers. Management of Raynaud’s phenomenon involves referral to secondary care for patients with suspected secondary Raynaud’s phenomenon. First-line treatment includes calcium channel blockers such as nifedipine. In severe cases, IV prostacyclin (epoprostenol) infusions may be used, and their effects may last for several weeks or months.

Chronic kidney disease (CKD) increases the risk of developing osteoporosis, a condition characterized by a T score < -2.5 on DEXA scan. CKD affects the metabolic pathways involved in vitamin D synthesis and serum phosphate levels, leading to increased parathyroid hormone (PTH) secretion and osteoclast activation, which contribute to the development of osteoporosis. Ethnicity, including being Brazilian, does not affect the risk of developing osteoporosis. However, being Asian or Caucasian is associated with a higher risk, although the reasons for this are not fully understood. Smoking is a significant risk factor for osteoporosis, and non-smokers are relatively protected against it. Smoking affects bone metabolism by limiting oxygen supply to the bones, slowing down osteoblast production, and reducing calcium absorption. Contrary to popular belief, obesity is not a risk factor for osteoporosis. In fact, a low body mass index is associated with a higher risk. This is because extra weight stresses the bone, which stimulates the formation of new bone tissue. Additionally, adipose tissue is a source of estrogen synthesis, which helps prevent bone density loss. Understanding the Causes of Osteoporosis Osteoporosis is a condition that affects the bones, making them weak and brittle. It is more common in women and older adults, with the prevalence increasing significantly in women over the age of 80. However, there are many other risk factors and secondary causes of osteoporosis that should be considered. Some of the most important risk factors include a history of glucocorticoid use, rheumatoid arthritis, alcohol excess, parental hip fracture, low body mass index, and smoking. Other risk factors include a sedentary lifestyle, premature menopause, certain ethnicities, and endocrine disorders such as hyperthyroidism and diabetes mellitus. There are also medications that may worsen osteoporosis, such as SSRIs, antiepileptics, and proton pump inhibitors. If a patient is diagnosed with osteoporosis or has a fragility fracture, further investigations may be necessary to identify the cause and assess the risk of subsequent fractures. Recommended investigations include blood tests, bone densitometry, and other procedures as indicated. It is important to identify the cause of osteoporosis and contributory factors in order to select the most appropriate form of treatment. As a minimum, all patients should have a full blood count, urea and electrolytes, liver function tests, bone profile, CRP, and thyroid function tests.

Before prescribing bisphosphonates for a patient with osteoporosis, it is important to correct any deficiencies in calcium and vitamin D. This is especially crucial for patients with hypocalcemia or vitamin D deficiency, as bisphosphonates can worsen these conditions by reducing calcium efflux from bones. In this case, the patient should receive calcium and vitamin D supplements before starting on alendronic acid. Hormone replacement therapy is not recommended for osteoporosis prevention, and vitamin D and alendronic acid should not be prescribed without also addressing calcium deficiencies.

Bisphosphonates: Uses and Adverse Effects

Bisphosphonates are drugs that mimic the action of pyrophosphate, a molecule that helps prevent bone demineralization. They work by inhibiting osteoclasts, which are cells that break down bone tissue. This reduces the risk of bone fractures and can be used to treat conditions such as osteoporosis, hypercalcemia, Paget’s disease, and pain from bone metastases.

However, bisphosphonates can have adverse effects, including oesophageal reactions such as oesophagitis and ulcers, osteonecrosis of the jaw, and an increased risk of atypical stress fractures of the proximal femoral shaft in patients taking alendronate. Patients may also experience an acute phase response, which can cause fever, myalgia, and arthralgia. Hypocalcemia, or low calcium levels, can also occur due to reduced calcium efflux from bone, but this is usually not clinically significant.

To minimize the risk of adverse effects, patients taking oral bisphosphonates should swallow the tablets whole with plenty of water while sitting or standing. They should take the medication on an empty stomach at least 30 minutes before breakfast or other oral medications and remain upright for at least 30 minutes after taking the tablet. Hypocalcemia and vitamin D deficiency should be corrected before starting bisphosphonate treatment, and calcium supplements should only be prescribed if dietary intake is inadequate. The duration of bisphosphonate treatment varies depending on the patient’s level of risk, and some authorities recommend stopping treatment after five years for low-risk patients with a femoral neck T-score of > -2.5.

Classification of Hypersensitivity Reactions

Hypersensitivity reactions are classified into four types according to the Gell and Coombs classification. Type I, also known as anaphylactic hypersensitivity, occurs when an antigen reacts with IgE bound to mast cells. This type of reaction is responsible for anaphylaxis and atopy, such as asthma, eczema, and hay fever. Type II, or cytotoxic hypersensitivity, happens when cell-bound IgG or IgM binds to an antigen on the cell surface. This type of reaction is associated with autoimmune hemolytic anemia, ITP, Goodpasture’s syndrome, and other conditions. Type III, or immune complex hypersensitivity, occurs when free antigen and antibody (IgG, IgA) combine to form immune complexes. This type of reaction is responsible for serum sickness, systemic lupus erythematosus, post-streptococcal glomerulonephritis, and extrinsic allergic alveolitis. Type IV, or delayed hypersensitivity, is T-cell mediated and is responsible for tuberculosis, graft versus host disease, allergic contact dermatitis, and other conditions.

In recent times, a fifth category has been added to the classification of hypersensitivity reactions. Type V hypersensitivity occurs when antibodies recognize and bind to cell surface receptors, either stimulating them or blocking ligand binding. This type of reaction is associated with Graves’ disease and myasthenia gravis. Understanding the different types of hypersensitivity reactions is important in diagnosing and treating various conditions. Proper identification of the type of reaction can help healthcare professionals provide appropriate treatment and management strategies.

Hip fracture surgery aims to enable immediate weight bearing to reduce complications associated with immobility. The BOA recommends unrestricted weight bearing to shorten hospital stays and improve patient compliance. The dynamic hip screw requires weight bearing for proper compression of the fracture site.

Hip fractures are a common occurrence, particularly in elderly women with osteoporosis. The femoral head’s blood supply runs up the neck, making avascular necrosis a potential risk in displaced fractures. Symptoms of a hip fracture include pain and a shortened and externally rotated leg. Patients with non-displaced or incomplete neck of femur fractures may still be able to bear weight. Hip fractures can be classified as intracapsular or extracapsular, with the Garden system being a commonly used classification system. Blood supply disruption is most common in Types III and IV fractures.

Intracapsular hip fractures can be treated with internal fixation or hemiarthroplasty if the patient is unfit. Displaced fractures are recommended for replacement arthroplasty, such as total hip replacement or hemiarthroplasty, according to NICE guidelines. Total hip replacement is preferred over hemiarthroplasty if the patient was able to walk independently outdoors with the use of a stick, is not cognitively impaired, and is medically fit for anesthesia and the procedure. Extracapsular hip fractures can be managed with a dynamic hip screw for stable intertrochanteric fractures or an intramedullary device for reverse oblique, transverse, or subtrochanteric fractures.

Common Causes of Elbow Pain

Elbow pain can be caused by a variety of conditions, each with their own characteristic features. Lateral epicondylitis, also known as tennis elbow, is characterized by pain and tenderness localized to the lateral epicondyle. Pain is worsened by resisted wrist extension with the elbow extended or supination of the forearm with the elbow extended. Episodes typically last between 6 months and 2 years, with acute pain lasting for 6-12 weeks.

Medial epicondylitis, or golfer’s elbow, is characterized by pain and tenderness localized to the medial epicondyle. Pain is aggravated by wrist flexion and pronation, and symptoms may be accompanied by numbness or tingling in the 4th and 5th finger due to ulnar nerve involvement.

Radial tunnel syndrome is most commonly due to compression of the posterior interosseous branch of the radial nerve, and is thought to be a result of overuse. Symptoms are similar to lateral epicondylitis, but the pain tends to be around 4-5 cm distal to the lateral epicondyle. Symptoms may be worsened by extending the elbow and pronating the forearm.

Cubital tunnel syndrome is due to the compression of the ulnar nerve. Initially, patients may experience intermittent tingling in the 4th and 5th finger, which may be worse when the elbow is resting on a firm surface or flexed for extended periods. Later, numbness in the 4th and 5th finger with associated weakness may occur.

Olecranon bursitis is characterized by swelling over the posterior aspect of the elbow, with associated pain, warmth, and erythema. It typically affects middle-aged male patients. Understanding the characteristic features of these conditions can aid in their diagnosis and treatment.

Polymyalgia rheumatica typically presents with normal levels of creatine kinase, while patients are likely to have elevated ESR and CRP at the time of diagnosis. Unlike polymyositis, which is more commonly associated with muscle weakness, PMR does not cause an increase in CK levels. Additionally, a raised anti-CCP is typically indicative of rheumatoid arthritis.

Polymyalgia Rheumatica: A Condition of Muscle Stiffness in Older People

Polymyalgia rheumatica (PMR) is a common condition that affects older people. It is characterized by muscle stiffness and elevated inflammatory markers. Although it is closely related to temporal arthritis, the underlying cause is not fully understood, and it does not appear to be a vasculitic process. PMR typically affects patients over the age of 60 and has a rapid onset, usually within a month. Patients experience aching and morning stiffness in proximal limb muscles, along with mild polyarthralgia, lethargy, depression, low-grade fever, anorexia, and night sweats.

To diagnose PMR, doctors look for raised inflammatory markers, such as an ESR of over 40 mm/hr. Creatine kinase and EMG are normal. Treatment for PMR involves prednisolone, usually at a dose of 15 mg/od. Patients typically respond dramatically to steroids, and failure to do so should prompt consideration of an alternative diagnosis.

Polymyalgia rheumatica is the most likely diagnosis based on the patient’s symptoms. The pain affecting both the pelvic and shoulder girdle in a bilateral manner, without any signs of weakness or wasting, is typical of this condition. Additionally, the patient’s age and gender are also consistent with a diagnosis of polymyalgia rheumatica.

The recommended first-line investigation for this condition is to check the blood inflammatory markers, specifically the ESR and CRP. These markers are often elevated in polymyalgia rheumatica and typically return to normal levels following steroid treatment. An antibody screen is not necessary as this condition is not associated with auto-antibodies.

A full-body MRI is not appropriate as it is not a specific test for polymyalgia rheumatica and is typically reserved for more invasive investigations. Ultrasound of the affected joints is also not necessary as there are no structural abnormalities associated with this condition that would be detected by this test. Similarly, X-rays of the shoulders and hips would not aid in the diagnosis of polymyalgia rheumatica as they do not provide visualization of the muscle.

Polymyalgia Rheumatica: A Condition of Muscle Stiffness in Older People

Polymyalgia rheumatica (PMR) is a common condition that affects older people. It is characterized by muscle stiffness and elevated inflammatory markers. Although it is closely related to temporal arthritis, the underlying cause is not fully understood, and it does not appear to be a vasculitic process. PMR typically affects patients over the age of 60 and has a rapid onset, usually within a month. Patients experience aching and morning stiffness in proximal limb muscles, along with mild polyarthralgia, lethargy, depression, low-grade fever, anorexia, and night sweats.

To diagnose PMR, doctors look for raised inflammatory markers, such as an ESR of over 40 mm/hr. Creatine kinase and EMG are normal. Treatment for PMR involves prednisolone, usually at a dose of 15 mg/od. Patients typically respond dramatically to steroids, and failure to do so should prompt consideration of an alternative diagnosis.